Mustafa Ozguroglu - Dissemin

Language
Login

All papers authored by Mustafa Ozguroglu

This paper is made freely available by the publisher.

2024 Joaquin Mateo

ORCID

, Johann S. de Bono

ORCID

ORCID

ORCID

ORCID

, Shahneen Sandhu

ORCID

ORCID

, Neeraj Agarwal

ORCID

ORCID

, Antoine Thiery-Vuillemin, Mustafa Özgüroğlu

ORCID

ORCID

, Nobuaki Matsubara, Jae Young Joung

ORCID

, Charles Padua and 8 other authors

Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial

Download from doi.org

This paper was not found in any repository, but could be made available legally by the author.

2023 A. O. Siefker-Radtke, N. Matsubara, Patricia Bastick, Sanjeev Sewak, Ben Tran, Martin Pichler, S. H. Park, Shahrokh Shariat, Sylvie Rottey, Peter Schatteman, Dirk Schrijvers, Vincent Verschaeve, Christof Vulsteke

ORCID

, Luiza Aleixo Barros Leite Ferreira, R. A. Huddart and 165 other authors

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

Upload

This paper is made freely available by the publisher.

2022 İrfan Cicin

ORCID

, Mohammed Oukkal

ORCID

, Hassen Mahfouf

ORCID

ORCID

, Blaha Larbaoui

ORCID

, Slim Ben Ahmed

ORCID

, Hassan Errihani

ORCID

, Khalid Alsaleh

ORCID

, Rhizlane Belbaraka

ORCID

, Perran Fulden Yumuk

ORCID

ORCID

, Mustafa Özgüroğlu

ORCID

An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction

Download from doi.org

This paper is made freely available by the publisher.

Manish A. Shah

ORCID

, Anghel Adrian Udrea, Igor Bondarenko, Was Mansoor, Raquel Guardeño Sánchez, Tomasz Sarosiek, Silvia Bozzarelli

ORCID

, Michael Schenker, Carlos Gomez-Martin, Carys Morgan, Mustafa Özgüroğlu

ORCID

, Joanna Pikiel, Haralabos P. Kalofonos, Elzbieta Wojcik, Tomas Buchler

ORCID

and 15 other authors

Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies

Download from doi.org

This paper is made freely available by the publisher.

David R. Spigel

ORCID

, Corinne Faivre-Finn

ORCID

, Jhanelle E. Gray, David Vicente, David Planchard

ORCID

, Luis Paz-Ares

ORCID

, Johan F. Vansteenkiste

ORCID

, Marina C. Garassino

ORCID

, Rina Hui, Xavier Quantin, Andreas Rimner

ORCID

ORCID

, Mustafa Özgüroğlu

ORCID

ORCID

, Terufumi Kato

ORCID

and 10 other authors

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

Download from doi.org

This paper was not found in any repository, but could be made available legally by the author.

Sherko Kuemmel

ORCID

, Mario Campone

ORCID

, Delphine Loirat, Rafael Lopez Lopez, J. Thaddeus Beck

ORCID

, Michelino De Laurentiis

ORCID

ORCID

ORCID

ORCID

, Guenther G. Steger

ORCID

, Esther Zamora Adelantado

ORCID

, Francois P. Duhoux

ORCID

, Richard Greil, Irene Kuter

ORCID

ORCID

and 13 other authors

A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer

Upload

This paper is made freely available by the publisher.

2021 Kim N. Chi

ORCID

, Simon Chowdhury, Anders Bjartell

ORCID

, Byung Ha Chung

ORCID

, Andrea J. Pereira de Santana Gomes

ORCID

, Robert Given, Alvaro Juárez, Axel S. Merseburger, Mustafa Özgüroğlu

ORCID

, Hirotsugu Uemura, Dingwei Ye

ORCID

, Sabine Brookman-May, Suneel D. Mundle

ORCID

, Sharon A. McCarthy, Julie S. Larsen and 5 other authors

Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study

Download from doi.org

Distributing this paper is prohibited by the publisher

Joseph Chao, Charles S. Fuchs, Kohei Shitara, Josep Tabernero, Kei Muro, Eric Van Cutsem, Yung-Jue Bang, Ferdinando De Vita, Gregory Landers, Chia-Jui Yen, Ian Chau, Anneli Elme, Jeeyun Lee, Mustafa Özgüroglu

ORCID

, Daniel Catenacci and 7 other authors

Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials

Upload

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

H. Bischoff, N. Reinmuth, M. Dvorkin, M. C. Garassino, D. Trukhin, M. J. Hochmair, M. Özgüroğlu

ORCID

, L. Havel, J. W. Goldman, Y. Chen, G. Losonczy, F. Spinnato, N. V. Conev, J. Bar, H. Broadhurst and 4 other authors

Erstlinienbehandlung mit Durvalumab plus Platin-Etoposid beim ED-SCLC: Explorative Analysen basierend auf dem Ausmaß der Erkrankung in CASPIAN

Upload

This paper is made freely available by the publisher.

Chantal Pauli, Tilmann Bochtler, Linda Mileshkin, Giulia Baciarello, Ferran Losa, Jeffrey S. Ross, George Pentheroudakis, George Zarkavelis, Suayib Yalcin, Mustafa Özgüroğlu

ORCID

, Andreas Beringer, Jeremy Scarato, Mathis Mueller-Ohldach, Marlene Thomas, Holger Moch and 1 other authors

A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience

Download from onlinelibrary.wiley.com

This paper is made freely available by the publisher.

Kim N. Chi, Andrea Juliana Pereira de Santana Gomes, Simon Chowdhury, Anders Bjartell, Byung Ha Chung, Andrea Juliana Pereira de Santana Gomes, Robert Given, Álvaro Juárez Soto, Alvaro Juarez Soto, Axel Stuart Merseburger, Mustafa Ozguroglu

ORCID

, Hirotsugu Uemura, Ye Dingwei, Spyros Triantos, Suneel Mundle and 7 other authors

Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).

Download from doi.org

This paper is made freely available by the publisher.

Yohann Loriot, Ajjai Shivaram Alva, Tibor Csőszi, Mustafa Ozguroglu

ORCID

, Nobuaki Matsubara, Lajos Geczi, Susanna Y. Cheng, Yves Fradet, Stephane Oudard, Christof Vulsteke

ORCID

, Rafael Morales-Barrera, Aude Flechon, Seyda Gunduz, Alejo Rodriguez-Vida, Ronac Mamtani and 5 other authors

Post-hoc analysis of long-term outcomes in patients with CR, PR, or SD to pembrolizumab (pembro) or platinum-based chemotherapy (chemo) as 1L therapy for advanced urothelial carcinoma (UC) in KEYNOTE-361.

Download from doi.org

This paper is made freely available by the publisher.

Emre Yekeduz, Nihan Şentürk Öztaş, Ismail Erturk, Deniz Tural, Nuri Karadurmus, Serdar Karakaya, Mutlu Hizal, Çağatay Arslan, Hakan Taban, Ahmet Küçükarda, Nihan Senturk Oztas, Ozlem Nuray Sever, Gokhan Ucar, Gokhan Uçar, Mehmet Ali Nahit Sendur and 6 other authors

Nivolumab as second-line treatment and beyond for metastatic renal cell carcinoma: A real-life experience from Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.

Download from doi.org

This paper is made freely available by the publisher.

Ajjai Shivaram Alva, Tibor Csőszi, Mustafa Ozguroglu

ORCID

, Nobuaki Matsubara, Lajos Geczi, Susanna Y. Cheng, Yves Fradet, Stephane Oudard, Christof Vulsteke

ORCID

, Rafael Morales-Barrera, Aude Flechon, Seyda Gunduz, Yohann Loriot, Alejo Rodriguez-Vida, Ronac Mamtani and 5 other authors

Impact of subsequent therapy on survival in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as first-line therapy for advanced urothelial carcinoma (UC).

Download from doi.org

This paper is made freely available by the publisher.

Thomas Powles, Tibor Csőszi, Mustafa Ozguroglu

ORCID

, Nobuaki Matsubara, Lajos Geczi, Susanna Y. Cheng, Yves Fradet, Stephane Oudard, Christof Vulsteke

ORCID

, Rafael Morales-Barrera, Aude Flechon, Seyda Gunduz, Yohann Loriot, Alejo Rodriguez-Vida, Ronac Mamtani and 5 other authors

1L pembrolizumab (pembro) versus chemotherapy (chemo) for choice-of-carboplatin patients with advanced urothelial carcinoma (UC) in KEYNOTE-361.

Download from doi.org

This paper is made freely available by the publisher.

Mustafa Ozguroglu

ORCID

, Ajjai Shivaram Alva, Tibor Csőszi, Nobuaki Matsubara, Lajos Geczi, Susanna Y. Cheng, Yves Fradet, Stephane Oudard, Christof Vulsteke

ORCID

, Rafael Morales-Barrera, Aude Flechon, Seyda Gunduz, Yohann Loriot, Alejo Rodriguez-Vida, Ronac Mamtani and 5 other authors

Analysis of PFS2 by subsequent therapy in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as 1L therapy for advanced urothelial carcinoma (UC).

Download from doi.org

This paper is made freely available by the publisher.

Marina C. Garassino

ORCID

, Luis Paz-Ares, Rina Hui, Corinne Faivre-Finn, Alex Spira, David Planchard, Mustafa Özgüroğlu

ORCID

, Davey Daniel, David Vicente, Shuji Murakami, Corey Langer, Suresh Senan, David Spigel, Anna Rydén, Yiduo Zhang and 3 other authors

Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable, stage III non-small-cell lung cancer

Download from doi.org

This paper was not found in any repository, but could be made available legally by the author.

Keunchil Park, Mustafa Özgüroğlu

ORCID

, Johan Vansteenkiste, David Spigel, James C.-H. Yang, Marcis Bajars, Mary Ruisi, Juliane Manitz, Fabrice Barlesi

Impact of Subsequent Immune Checkpoint Inhibitor Treatment on Overall Survival With Avelumab vs Docetaxel in Platinum-Treated Advanced NSCLC: Post Hoc Analyses From the Phase 3 JAVELIN Lung 200 Trial

Upload

This paper was not found in any repository, but could be made available legally by the author.

Ahmet Sezer, Saadettin Kilickap, Mahmut Gümüş, Igor Bondarenko, Mustafa Özgüroğlu

ORCID

, Miranda Gogishvili, Haci M. Turk, Irfan Cicin, Dmitry Bentsion, Oleg Gladkov, Philip Clingan, Virote Sriuranpong, Naiyer Rizvi, Bo Gao, Siyu Li and 12 other authors

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

Upload

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

N. Reinmuth, M. C. Garassino, D. Trukhin, M. J. Hochmair, M. Ozguroglu

ORCID

, L. Havel, J. Goldman, Y. Chen, G. Losonczy, F. Spinnato, N. Conev, J. Bar, H. Broadhurst, N. Byrne, H. Jiang and 1 other authors

First-Line Durvalumab plus Platinum-Etoposide in ES-SCLC: Exploratory Analyses Based on Extent of Disease in CASPIAN

Upload

Missing publications? Search for publications with a matching author name.